File
Authors
Honda, Masashi Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University Researchers DB KAKEN
Kimura, Yusuke Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University Researchers DB
Teraoka, Shogo Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University
Kawamoto, Bunya Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University Researchers DB KAKEN
Morizane, Shuichi Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University Researchers DB KAKEN
Hikita, Katsuya Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University Researchers DB KAKEN
Takenaka, Atsushi Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University Researchers DB KAKEN
Keywords
benign prostatic hyperplasia
combination treatment
phosphodiesterase type 5 inhibitor
storage symptoms
β3-adrenoreceptor agonist
Abstract
Background: The aim of this study is to evaluate the efficacy and safety of tadalafil, a phosphodiesterase type 5 inhibitor, plus mirabegron, a β3-adrenoreceptor agonist, in patients with benign prostatic hyperplasia who presented with persistent storage symptoms after tadalafil monotreatment. Methods: The registration of this study started in August 2016 and ended in July 2019. The inclusion criteria included patients aged ? 50 years who were diagnosed with benign prostatic hyperplasia and who presented with overactive bladder symptoms. Patients were treated with oral tadalafil 5 mg once daily for 4 weeks. Then, its efficacy was evaluated. Patients who responded to the treatment received oral tadalafil 5 mg once daily for 4 more weeks (monotreatment group). Meanwhile, those who did not respond received oral tadalafil 5 mg and mirabegron 50 mg, which is an add-on treatment, once daily for 4 more weeks (combination therapy group). Results: After 8 weeks, the monotreatment group (n = 19) and the combination group (n = 56) had significantly better total Overactive Bladder Symptom Score and International Prostate Symptom Score and International Prostate Symptom Score voiding and storage subscale scores. Moreover, the two groups experienced significant improvements in the total Overactive Bladder Questionnaire and Nocturia Quality of Life Questionnaire scores, and Nocturia Quality of Life Questionnaire Bother/Concern subscale score after 8 weeks. However, there were no cases of urinary retention or serious adverse events. Conclusion: Combination treatment with tadalafil and mirabegron is effective and safe for patients with benign prostatic hyperplasia who presented with persistent storage symptoms after tadalafil monotreatment. Hence, tadalafil plus mirabegron is a promising therapeutic option, and it can improve overactive bladder related-quality of life.
Publisher
Tottori University Medical Press
Content Type
Journal Article
Link
ISSN
05135710
EISSN
13468049
NCID
AA00892882
Journal Title
Yonago Acta Medica
Current Journal Title
Yonago Acta Medica
Volume
65
Issue
3
Start Page
231
End Page
237
Published Date
2022-08-29
Publisher-DOI
Text Version
Publisher
Rights
(C) 2022 Tottori University Medical Press.
Citation
Yonago Acta Medica. 2022, 65(3), 231-237. doi10.33160/yam.2022.08.009
Department
Faculty of Medicine/Graduate School of Medical Sciences/University Hospital
Language
English